Three-fourths of patients have 70-75% improvement at 16 weeks with zasocitinib, envudeucit ...

Esperion announced the expansion of its development portfolio with a new program aimed at treating primary sclerosing cholangitis (PSC), a rare liver disease. The company confirmed the effectiveness ...

We explore what allosteric modulators are, their benefits and drawbacks, and which candidates are currently advancing through ...

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize ...

Brepocitinib significantly boosts global, all secondary dermatomyositis scores in VALOR tr ...

Abstract Highlights Rinzimetostat is a potent and highly selective next-generation allosteric PRC2 inhibitor targeting the EED subunit that has demonstrated potential best-in-class efficacy and safety ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Neuron23 ® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological ...

WALTHAM, Mass.--(BUSINESS WIRE)--Ensem Therapeutics, Inc. (ENSEM), a pioneering drug discovery and development company that leverages its unique Kinetic Ensemble® platform to advance innovative small ...

On March 25, 2026, Merck, known as MSD outside the United States andCanada, announced it has entered into a definitive ...